NCT04442945View on ClinicalTrials.gov

Phase 1 Study of ANAVEX3-71

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 3, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

October 30, 2021

Conditions
Healthy
Interventions
DRUG

ANAVEX3-71

Active oral dose of ANAVEX3-71

DRUG

Placebo

Oral placebo

Trial Locations (1)

5000

CMAX Clinical Research Pty Ltd, Adelaide

Sponsors
All Listed Sponsors
collaborator

Anavex Australia Pty Ltd.

INDUSTRY

lead

Anavex Life Sciences Corp.

INDUSTRY